Posted inPharmaceutical
RougeTx Launches with $58 Million Series A to Advance HHT Therapy RTX-001
RougeTx launches with a $58M Series A to take oral HHT therapy RTX-001 toward the clinic. Investors, how it works and what comes next.
Posted inPharmaceutical
Roche Bets Up to $1.27 Billion on Alector’s Brain-Penetrating Parkinson’s Therapy AL050
Genentech, part of Roche, licenses Alector AL050, a brain-penetrant GCase enzyme for Parkinson's, in a deal worth up to $1.27 billion.
Posted inPharmaceutical
Samfara Acquires Chr. Olesen Synthesis to Expand Pharmaceutical API Business
Samfara completed its first investment, buying Danish controlled-substance API maker Chr. Olesen Synthesis. What the plant makes and why it matters.
Posted inPharmaceutical
Replimune Launches TUDRIQEV in US for Advanced Melanoma Following FDA Approval
Tudriqev, used with nivolumab, is now available in the US for advanced melanoma after PD-1 therapy, following accelerated FDA approval.
Posted inPharmaceutical
Datroway Plus Ivonescimab: What the TROP2 ADC and PD-1/VEGF Combination Aims to Do in Breast and Lung Cancer
Why pair an ADC with a PD-1/VEGF antibody? What Datroway and ivonescimab do, the TNBC data so far and what remains unproven.
Posted inPharmaceutical
TIL Healthcare Pharma Plant Blast in Andhra Pradesh’s Sri City Leaves Workers Dead and Injured
A boiler explosion at the TIL Healthcare unit in Sri City, Andhra Pradesh killed five workers and injured over 10 on 3 October; the cause is under probe.
Posted inPharmaceutical
FDA Approves Lilly Jaypirca as First-Line CLL/SLL Treatment
FDA approved Lilly Jaypirca (pirtobrutinib) for previously untreated CLL/SLL without 17p deletion on 2 October, based on the BRUIN CLL-313 trial.
Posted inPharmaceutical
Mironid LoAc Phase 1 Trial Begins Dosing for ADPKD Drug
Mironid LoAc Phase 1 dosing has begun: the first-in-class PDE4 activator for ADPKD is being tested for safety and pharmacokinetics in healthy volunteers.
Posted inPharmaceutical
Foghorn FHD-909 Program Ends With 40% Workforce Cut
Foghorn FHD-909 program ends: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn will cut about 40% of staff.
Posted inPharmaceutical
Sanofi Regeneron Alliance: Up to $8 Billion Immunology Deal
Sanofi Regeneron alliance expands: Sanofi pays $1 billion upfront and up to $7 billion in milestones for four long-acting immunology antibodies.